Table of Contents
Cardiovascular Psychiatry and Neurology
Volume 2009 (2009), Article ID 107286, 9 pages
http://dx.doi.org/10.1155/2009/107286
Research Article

Role of Hypertension in Aggravating A Neuropathology of AD Type and Tau-MediatedMotor Impairment

1Department of Psychiatry, Mount Sinai School of Medicine, New York, NY10029, USA
2Alzheimer Disease Research Unit, CIEN Foundation-Reina Sofia Foundation, Valderrebollo 5, 28031 Madrid, Spain
3GRECC, James J. Peters Veterans Affairs Medical Center, Bronx, NY 10468, USA

Received 8 April 2009; Revised 19 June 2009; Accepted 2 July 2009

Academic Editor: Christian Humpel

Copyright © 2009 C. Díaz-Ruiz et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. K. Ziegler-Graham, R. Brookmeyer, E. Johnson, and H. M. Arrighi, “Worldwide variation in the doubling time of Alzheimer's disease incidence rates,” Alzheimer's and Dementia, vol. 4, no. 5, pp. 316–323, 2008. View at Publisher · View at Google Scholar
  2. M. J. Stampfer, “Cardiovascular disease and Alzheimer's disease: common links,” Journal of Internal Medicine, vol. 260, no. 3, pp. 211–223, 2006. View at Publisher · View at Google Scholar
  3. I. Skoog and D. Gustafson, “Update on hypertension and Alzheimer's disease,” Neurology Research, vol. 28, no. 6, pp. 605–611, 2006. View at Publisher · View at Google Scholar
  4. K. M. Bellew, J. G. Pigeon, P. E. Stang, W. Fleischman, R. M. Gardner, and W. W. Baker, “Hypertension and the rate of cognitive decline in patients with dementia of the Alzheimer type,” Alzheimer Disease and Associated Disorders, vol. 18, no. 4, pp. 208–213, 2004. View at Google Scholar
  5. D. L. Sparks, S. W. Scheff, H. Liu et al., “Increased density of senile plaques (SP), but not neurofibrillary tangles (NFT), in non-demented individuals with the apolipoprotein E4 allele: comparison to confirmed Alzheimer's disease patients,” Journal of Neurological Sciences, vol. 138, no. 1-2, pp. 97–104, 1996. View at Publisher · View at Google Scholar
  6. H. Petrovitch, L. R. White, G Izmirilian et al., “Midlife blood pressure and neuritic plaques, neurofibrillary tangles, and brain weight at death: the HAAS. Honolulu-Asia aging Study,” Neurobiology of Aging, vol. 21, no. 1, pp. 57–62, 2000. View at Google Scholar
  7. J. Ghika and J. Bogousslavsky, “Presymptomatic hypertension is a major feature in the diagnosis of progressive supranuclear palsy,” Archives of Neurology, vol. 54, no. 9, pp. 1104–1108, 1997. View at Google Scholar
  8. S. Papapetropoulos, C. Singer, D. McCorquodale, J. Gonzalez, and D. C. Mash, “Cause, seasonality of death and co-morbidities in progressive supranuclear palsy (PSP),” Parkinsonism and Related Disorders, vol. 11, no. 7, pp. 459–463, 2005. View at Publisher · View at Google Scholar
  9. C. Colosimo, Y. Osaki, N. Vanacore, and A. J. Lees, “Lack of association between progressive supranuclear palsy and arterial hypertension: a clinicopathological study,” Journal of the Movement Disorders, vol. 18, no. 6, pp. 694–697, 2003. View at Publisher · View at Google Scholar
  10. I. Sibon, F. Macia, A. Vital, A. Delacourte, and F. Tison, “Hypertension and progressive supranuclear palsy: is everything so clear?” Journal of the Movement Disorders, vol. 19, no. 10, pp. 1259–1261, 2004. View at Publisher · View at Google Scholar
  11. K. Hsiao, P. Chapman, S. Nilsen et al., “Correlative memory deficits, Aß elevation, and amyloid plaques in transgenic mice,” Science, vol. 4, no. 5284, pp. 99–102, 1996. View at Publisher · View at Google Scholar
  12. J. Lewis, E. McGowan, J. Rockwood et al., “Neurofibrillary tangles, amyotrophy and progressive motor disturbance in mice expressing mutant (P301L) tau protein,” Nature Genetics, vol. 25, no. 4, pp. 402–405, 2000. View at Publisher · View at Google Scholar
  13. R. Morris, “Developments of a water-maze procedure for studying spatial learning in the rat,” Journal of Neuroscience Methods, vol. 11, no. 1, pp. 47–60, 1984. View at Publisher · View at Google Scholar
  14. S. Le Corre, H. W. Klafki, N. Plesnila et al., “An inhibitor of tau hyperphosphorylation prevents severe motor impairments in tau transgenic mice,” Proceedings of the National Academy of Sciences of the United States of America, vol. 103, no. 25, pp. 9673–9678, 2006. View at Publisher · View at Google Scholar
  15. J. Wang, L. Ho, L. Chen et al., “Valsartan lowers brain betaamyloid protein levels and improves spatial learning in a mouse model of Alzheimer disease,” The Journal of Clinical Investigation, vol. 117, no. 11, pp. 3393–3402, 2007. View at Publisher · View at Google Scholar
  16. Z. Berger, H. Roder, A. Hanna et al., “Accumulation of pathological tau species and memory loss in a conditional model of tauopathy,” Journal of Neuroscience, vol. 27, no. 14, pp. 3650–3662, 2007. View at Publisher · View at Google Scholar
  17. M. T. Gentile, R. Poulet, A. Di Pardo et al., “ß-amyloid deposition in brain is enhanced in mouse models of arterial hypertension,” Neurobiology of Aging, vol. 30, no. 2, pp. 222–228, 2009. View at Publisher · View at Google Scholar
  18. B. B. Johansson, “Hypertension mechanisms causing stroke,” Clinical and Experimental Pharmacology and Physiology, vol. 26, no. 7, pp. 563–565, 1999. View at Publisher · View at Google Scholar
  19. F.-E. De Leeuw, F. Richard, J. C. de Groot et al., “Interaction between hypertension, apoE, and cerebral white matter lesions,” Stroke, vol. 35, no. 5, pp. 1057–1060, 2004. View at Publisher · View at Google Scholar
  20. D. Morgan, S. Munireddy, J. Alamed et al., “Apparent behavioral benefits of tau overexpression in P301L tau transgenic mice,” The Journal of Alzheimer's Disease, vol. 15, no. 4, pp. 605–614, 2008. View at Google Scholar